Goldman Sachs Cuts Gemini to Sell as Profitability Path Darkens
Weak volumes, smaller customer base and ongoing losses raise profitability doubts.
Already have an account? Sign in.
Weak volumes, smaller customer base and ongoing losses raise profitability doubts.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.